Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Challenging Adult and Pediatric Autoimmune Connective Tissue Disease Cases: Pearls for Diagnosis and Management
Description
The session discusses challenging cases of autoimmune connective tissue diseases, starting with a 38-year-old woman showing signs of systemic sclerosis, particularly the "puffy hand" sign, early edema, and features like Raynaud's phenomenon and nail fold capillary changes. It underscores the importance of early diagnosis and intervention with treatments like mycophenolate, which has been shown to improve skin involvement and lung disease associated with systemic sclerosis. The presentation transitions to a second case of a 52-year-old man exhibiting skin tightening indicative of eosinophilic fasciitis (EF), which differs from systemic sclerosis, notably by sparing the distal digits and lacking Raynaud's and nail changes. Findings such as the groove sign and seat belt sign support the EF diagnosis, which can be confirmed by MRI as a non-invasive method. Treatment for EF typically starts with systemic steroids, often combined with methotrexate or mycophenolate for better outcomes. Clinical pearls from both cases emphasize the critical need for early recognition and aggressive treatment to improve patient mobility and quality of life.
View moreConclusions
- Systemic sclerosis in its early phase can be treated effectively to reverse skin changes if recognized timely, marked by signs such as the puffy hand sign.
- Raynaud's phenomenon and nailfold capillary changes are important clues in diagnosing systemic sclerosis.
- Mycophenolate mofetil has shown effectiveness in reducing skin and lung disease severity in systemic sclerosis patients when started early.
- MRI is a useful diagnostic and monitoring tool in eosinophilic fasciitis, showing sensitivity comparable to fascial biopsy.
- Eosinophilic fasciitis can be distinguished from systemic sclerosis through physical examination findings such as distal sparing of digits, absence of Raynaud's, and specific skin signs.
- Combined treatment strategies involving systemic steroids and immunomodulatory agents like methotrexate or mycophenolate mofetil yield better results in eosinophilic fasciitis management.
- A Prospective Observational Study of Mycophenolate Mofetil Treatment in Progressive Diffuse Cutaneous Systemic Sclerosis of Recent Onset FABIAN A. MENDOZA, SARAH J. NAGLE, JASON B. LEE, and SERGIO A. JIMENEZ The Journal of Rheumatology 2012;
- Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja, Richard Silver, Virginia Steen, Charlie Strange, Robert Wise, Fredrick Wigley, Maureen Mayes, David J Riley, Sabiha Hussain, Shervin Assassi, Vivien M Hsu, Bela
- Shahriari, N ., Mazori, D. R ., Shahriari, M ., Taylor, D ., Shaw, K ., LaChance, A. H ., ... & Vleugels, R. A. (2023). Utility of magnetic resonance imaging in the diagnosis of eosinophilic fasciitis: A multicenter retrospective cohort study. Journal of the American Academy of Dermatology, 89(6), 1313-1315.
- Characteristics and Outcomes of Eosinophilic Fasciitis-Associated Monoclonal Gammopathy, Daniel R. Mazori, MD1,2,3; Bina Kassamali, BA1,2; Michelle S. Min, MD, MS1,2,4; Morgan Schaefer, BA1; Avery H. LaChance, MD, MPH1,2; Adam S. Sperling, MD, PhD2,5,6; Ruth Ann Vleugels, MD, MPH, MBA1,2 JAMA Dermatol. 2021;157(12):1508-1509. doi:10.1001/jamadermatol.2021.4302
- Wright, N. A ., Mazori, D. R ., Patel, M ., Merola, J. F ., Femia, A. N ., & Vleugels, R. A. (2016). Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA dermatology, 152(1), 97-99.
- Kelly Lo, BS,' Gabriela Cobos, MD,' Kristen Lo, Alisa N. Femia, MD. Intravenous immunoglobulin for refractory eosinophilic fasciitis: A retrospective analysis from 3 tertiary care centers J AM ACAD DERMATOL 1354 2023
- JAMA Dermatol. 2020;156(5):595-597. doi:10.1001/jamadermatol.2020.0120 Mycophenolate Mofetil for Eosinophilic Fasciitis A Retrospective Analysis From 3 Tertiary Care Centers